SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin edges higher on launching generic TRICOR tablets

20 Nov 2012 Evaluate

Lupin is currently trading at Rs 564.00, up by 1.90 points or 0.34% from its previous closing of Rs 562.10 on the BSE.

The scrip opened at Rs 573.00 and has touched a high and low of Rs 573.00 and Rs 558.60 respectively. So far 27571 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 631.90 on 10-Sep-2012 and a 52 week low of Rs 409.50 on 14-Dec-2011.

Last one week high and low of the scrip stood at Rs 588.90 and Rs 557.10 respectively. The current market cap of the company is Rs 25299.73 crore.

The promoters holding in the company stood at 46.89% while Institutions and Non-Institutions held 43.37% and 9.75% respectively.

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc, has launched its Fenofibrtae tablets, 48 mg and 145 mg strengths in the United States. The company has earlier received final approval for the same from the US Food and Drug Administration (USFDA).

Lupin’s Fenofibrtae tablets are the AB rated generic equivalent of Abbott’s TRICOR tablets and are indicated for primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott’s TRICOR tablets 48 mg and 145 mg had sales of $1.26 billion as per IMS Health, June, 2012.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2476.10 77.40 (3.23%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: